357 related articles for article (PubMed ID: 8103770)
1. Evidence against depletion of the growth hormone (GH)-releasable pool in human primary hypothyroidism: studies with GH-releasing hormone, pyridostigmine, and arginine.
Valcavi R; Valente F; Dieguez C; Zini M; Procopio M; Portioli I; Ghigo E
J Clin Endocrinol Metab; 1993 Sep; 77(3):616-20. PubMed ID: 8103770
[TBL] [Abstract][Full Text] [Related]
2. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
Procopio M; Invitti C; Maccario M; Grottoli S; Cavagnini F; Camanni F; Ghigo E
Int J Obes Relat Metab Disord; 1995 Feb; 19(2):108-12. PubMed ID: 7735336
[TBL] [Abstract][Full Text] [Related]
3. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
Cordido F; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
[TBL] [Abstract][Full Text] [Related]
4. Evidence that alpha 2-adrenergic pathways play a major role in growth hormone (GH) neuroregulation: alpha 2-adrenergic agonism counteracts the inhibitory effect of muscarinic cholinergic receptor blockade on the GH response to GH-releasing hormone, while alpha 2-adrenergic blockade diminishes the potentiating effect of increased cholinergic tone on such stimulation in normal men.
Devesa J; Diaz MJ; Tresguerres JA; Arce V; Lima L
J Clin Endocrinol Metab; 1991 Aug; 73(2):251-6. PubMed ID: 1677361
[TBL] [Abstract][Full Text] [Related]
5. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects.
Cordido F; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 1990 May; 70(5):1361-70. PubMed ID: 2159483
[TBL] [Abstract][Full Text] [Related]
6. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
Procopio M; Maccario M; Savio P; Valetto MR; Aimaretti G; Grottoli S; Oleandri SE; Baffoni C; Tassone F; Arvat E; Camanni F; Ghigo E
Minerva Endocrinol; 1999; 24(3-4):107-11. PubMed ID: 10953725
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone response to hexarelin, growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen in prepubertal and early pubertal short children.
Guzzaloni G; Grugni G; Morabito F
Minerva Endocrinol; 1998 Dec; 23(4):99-104. PubMed ID: 10361807
[TBL] [Abstract][Full Text] [Related]
8. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
Procopio M; Maccario M; Savio P; Valetto MR; Aimaretti G; Grottoli S; Oleandri SE; Baffoni C; Tassone F; Arvat E; Camanni F; Ghigo E
Panminerva Med; 1998 Mar; 40(1):13-7. PubMed ID: 9573747
[TBL] [Abstract][Full Text] [Related]
9. Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycemia on growth hormone (GH) releasing hormone-induced GH secretion in man: does acute hyperglycemia act through hypothalamic release of somatostatin?
Peñalva A; Burguera B; Casabiell X; Tresguerres JA; Dieguez C; Casanueva FF
Neuroendocrinology; 1989 May; 49(5):551-4. PubMed ID: 2566942
[TBL] [Abstract][Full Text] [Related]
10. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man.
Peñalva A; Carballo A; Pombo M; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1993 Jan; 76(1):168-71. PubMed ID: 8421084
[TBL] [Abstract][Full Text] [Related]
11. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects.
Arvat E; Gianotti L; Grottoli S; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
J Clin Endocrinol Metab; 1994 Nov; 79(5):1440-3. PubMed ID: 7962341
[TBL] [Abstract][Full Text] [Related]
12. Further evidence of cholinergic impairment of the neuroendocrine control of the GH secretion in Down's syndrome.
Beccaria L; Marziani E; Manzoni P; Arvat E; Valetto MR; Gianotti L; Ghigo E; Chiumello G
Dement Geriatr Cogn Disord; 1998; 9(2):78-81. PubMed ID: 9524798
[TBL] [Abstract][Full Text] [Related]
13. Effect of enhancement of endogenous cholinergic tone with pyridostigmine on the dose-response relationships of growth hormone (GH)-releasing hormone-induced GH secretion in normal subjects.
Peñalva A; Muruais C; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1990 Feb; 70(2):324-7. PubMed ID: 2105328
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone secretion in aging. Effect of pyridostigmine on growth hormone responsiveness to growth hormone-releasing hormone.
Giusti M; Marini G; Sessarego P; Peluffo F; Valenti S; Caratti C; Giordano G
Recenti Prog Med; 1991 Dec; 82(12):665-8. PubMed ID: 1815302
[TBL] [Abstract][Full Text] [Related]
15. The decrease in growth hormone (GH) response after repeated stimulation with GH-releasing hormone is partly caused by an elevation of somatostatin tonus.
Reichardt B; Schrader M; Mojto J; Mehltretter G; Müller OA; Schopohl J
J Clin Endocrinol Metab; 1996 May; 81(5):1994-8. PubMed ID: 8626871
[TBL] [Abstract][Full Text] [Related]
16. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man.
Ghigo E; Goffi S; Nicolosi M; Arvat E; Valente F; Mazza E; Ghigo MC; Camanni F
J Clin Endocrinol Metab; 1990 Dec; 71(6):1481-5. PubMed ID: 2229304
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone (GH) responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone.
Terzolo M; Bossoni S; Alí A; Doga M; Reimondo G; Milani G; Peretti P; Manelli F; Angeli A; Giustina A
J Clin Endocrinol Metab; 2000 Mar; 85(3):1310-5. PubMed ID: 10720081
[TBL] [Abstract][Full Text] [Related]
18. Glucocorticoids may inhibit growth hormone release by enhancing beta-adrenergic responsiveness in hypothalamic somatostatin neurons.
Lima L; Arce V; Diaz MJ; Tresguerres JA; Devesa J
J Clin Endocrinol Metab; 1993 Feb; 76(2):439-44. PubMed ID: 8094392
[TBL] [Abstract][Full Text] [Related]
19. Arginine normalizes the growth hormone (GH) response to GH-releasing hormone in adult patients receiving chronic daily immunosuppressive glucocorticoid therapy.
Giustina A; Bossoni S; Bodini C; Girelli A; Balestrieri GP; Pizzocolo G; Wehrenberg WB
J Clin Endocrinol Metab; 1992 Jun; 74(6):1301-5. PubMed ID: 1592874
[TBL] [Abstract][Full Text] [Related]
20. Pyridostigmine potentiates growth hormone (GH)-releasing hormone-induced GH release in both men and women.
Arvat E; Cappa M; Casanueva FF; Dieguez C; Ghigo E; Nicolosi M; Valcavi R; Zini M
J Clin Endocrinol Metab; 1993 Feb; 76(2):374-7. PubMed ID: 8432781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
